check_circleStudy Completed

Cancer

Expanded access to provide copanlisib for patients with cancer who are experiencing a positive response, as determined by their doctors

Trial purpose

The purpose of this Expanded Access Program (EAP) is to allow patients to continue receiving treatment with copanlisib if they are currently having, in the opinion of their healthcare provider, an objective favorable response when taking copanlisib. Patients considering this access program should have no other therapeutic option, have not developed a disease and/or medical condition (including pregnancy), and/or have a toxicity that would conflict with continuing to receive copanlisib.

Key Participants Requirements

Sex

All

Age

NaN - N/A

Trial summary

Enrollment Goal
N/A
Trial Dates
null - Today
Phase
N/A
Could I Receive a placebo
No
Products
Aliqopa (Copanlisib, BAY80-6946)
Accepts Healthy Volunteer
N/A

Where to participate

StatusInstitutionLocation
Not yet recruiting
Many LocationsMany Locations, Brazil
Not yet recruiting
Many LocationsMany Locations, Chile
Not yet recruiting
Many LocationsMany Locations, Hong Kong
Not yet recruiting
Many LocationsMany Locations, Hungary
Not yet recruiting
Many LocationsMany Locations, Ireland
Not yet recruiting
Many LocationsMany Locations, Malaysia
Not yet recruiting
Many LocationsMany Locations, Poland
Not yet recruiting
Many LocationsMany Locations, Romania
Not yet recruiting
Many LocationsMany Locations, Russian Federation
Not yet recruiting
Many LocationsMany Locations, Taiwan
Not yet recruiting
Many LocationsMany Locations, Ukraine

Trial design

Copanlisib Expanded Access Program (EAP) for patients who, in the opinion of their healthcare provider, are deriving benefit from copanlisib therapy
Trial Type
Expanded Access
Intervention Type
Drug
Trial Purpose
N/A
Allocation
N/A
Blinding
N/A
Assignment
N/A
Trial Arms
N/A